Osteitis

Subscribe to Selected New Research on Osteitis

515 relevant articles (34 outcomes, 27 trials/studies) found for this Disease

Also Known As:

Inflammation, Bone; Bone Inflammation

Relationship Network

Disease Context: Research Results

Bacterial Infections and Mycoses

Infection: 210887

Infectious Bone Diseases: 1

Osteitis: 515

Musculoskeletal Diseases: 83

Bone Diseases: 2380

Osteitis: 515

Infectious Bone Diseases: 1

Osteitis: 515

Related Diseases

1.	Osteomalacia
2.	Pain (Aches)
3.	Bone Diseases (Bone Disease)
4.	Acquired Hyperostosis Syndrome (SAPHO Syndrome)
5.	Secondary Hyperparathyroidism

Experts

1.	Mückley, T: 1 article (08/2008)
2.	Tiemann, A: 1 article (08/2008)
3.	Diefenbeck, M: 1 article (08/2008)
4.	Hofmann, G O: 1 article (08/2008)
5.	Hernández, M Victoria: 1 article (04/2008)
6.	Moll, Concepción: 1 article (04/2008)
7.	Gómez-Puerta, José A: 1 article (04/2008)
8.	Soriano, Alex: 1 article (04/2008)
9.	Cañete, Juan D: 1 article (04/2008)
10.	Sanmartí, Raimon: 1 article (04/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Osteitis:

1.	Calcitriol (Calcijex)FDA LinkGeneric 08/03/1989 - "We conclude that long-term intermittent infusions of intravenous calcitriol are effective in ameliorating osteitis fibrosa in patients on dialysis" 01/01/1996 - "The use of high-dose pulse intravenous, intraperitoneal, and oral calcitriol therapy has significantly decreased serum PTH levels and retarded the progression of osteitis fibrosa" 12/28/1989 - "Calcitriol for osteitis fibrosa." 01/01/1995 - "Intravenous calcitriol can increase bone mass in hemodialysis patients with osteitis fibrosa." 08/03/1989 - "Patients whose osteitis fibrosa is refractory to oral calcitriol and who are candidates for parathyroidectomy should be considered first for intravenous calcitriol therapy." Order ALL the reference details at left...
2.	CalciumIBA 03/01/2000 - "In conclusion, intravenous OCT effectively suppressed PTH secretion and improved the bone histological characteristics of severe osteitis fibrosa, especially in patients with initial serum calcium levels less than 10 mg/dL" 11/01/1979 - "Doses of 25-OHD3 capable to correct blood calcium levels and intestinal absorption of calcium, may have minimal benefit on the osteitis fibrosa component of the bone lesion." 06/23/1976 - "Dialysate calcium levels, dialysis hours and the healing of osteitis fibrosa." 03/01/1951 - "Treatment of osteitis with calcium dielectrolysis.]" 10/01/2000 - "Although bone biopsy represents the definitive diagnostic test to differentiate between osteitis fibrosa, low-turnover bone disease and bone involvement unrelated to disturbed calcium metabolism (i.e" Order ALL the reference details at left...
3.	pamidronate (APD)FDA LinkGeneric 12/01/2001 - "Intravenous pamidronate may constitute a safe and effective treatment option for patients with refractory osteitis pubis." 12/01/2001 - "We describe 3 cases, 2 with idiopathic osteitis pubis and one that was associated with a spondyloarthropathy, that failed to respond to conservative measures but experienced clinical remission with 3 to 6 monthly courses of intravenous pamidronate" 08/01/2008 - "These studies show that in this model of stage 3 renal disease, pamidronate increased mineral content in the femoral midshaft and distal metaphysis primarily by adding bone to endocortical and trabecular surfaces but did not reduce osteitis fibrosa." 06/01/2002 - "SAPHO syndrome is characterized by both increased bone remodeling and inflammatory osteitis, indicating that it may respond favorably to pamidronate's dual mechanism of action" 04/01/2002 - "These preliminary in vitro data support the potential use of APD in clinical conditions characterised by increased bone turnover such as osteomyelitis, osteitis, septic osteoarthritis, navicular disease, cystic bone lesions and immobilisation-induced osteoporosis and provide useful information for future pharmacokinetic studies and clinical trials in vivo." Order ALL the reference details at left...
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/01/1996 - "The osteoblastic apoptosis triggered by TNF-alpha-generated ceramide may explain the inhibition of bone formation during severe bone inflammation." 04/01/2008 - "CONCLUSIONS: Anti-TNF-alpha therapies are effective treatment for patients with refractory SAPHO syndrome, not only for cutaneous lesions but also for persistent bone lesions such as osteitis." 05/01/2004 - "In this study, these propositions were tested in two experiments by instilling IL-1beta or TNF-alpha into one knee of Lewis rats (n = 6/group) to incite arthritis, after which semiquantitative scores for inflammation, bone resorption, osteoclasts, and cartilage integrity were acquired" 04/01/2008 - "We describe 2 new cases with ilium osteitis as the main SAPHO syndrome feature and review reported cases treated with anti-TNF-alpha" 04/01/2008 - "OBJECTIVE: To analyze the clinical efficacy of anti-tumor necrosis factor (TNF)-alpha therapy in the SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome" Order ALL the reference details at left...
5.	Vitamin D FDA LinkGeneric 01/01/1979 - "Limitation by hyperphosphataemia of the "prophylactic" use of vitamin D metabolites in the treatment of osteitis fibrosa in patients on chronic haemodialysis." 06/01/1977 - "Treatment should involve prompt surgical repair and reversal of the osteitis fibrosa with an effective vitamin D metabolite such as 1alphaOHD3." 01/01/1983 - "In two patients osteomalacia disappeared, and in two patients osteitis fibrosa emerged but improved in one following vitamin D therapy" 11/01/2002 - "In contrast, osteitis fibrosa and parathyroid tumor weight changed very little in parts of the world where vitamin D depletion is endemic" 11/01/2002 - "Between 1945 and 1950, both the prevalence of osteitis fibrosa and parathyroid tumor weight declined dramatically in the United States, coinciding with fortification of milk with vitamin D" Order ALL the reference details at left...
6.	Anti-Bacterial Agents (Antibiotics)IBA 10/30/1999 - "In case of biopsy proven osteitis with positive culture, prolonged oral antibiotics are indicated" 05/01/1980 - "Osteitis pubis has not been a problem possibly because of the use of wide-spectrum antibiotics." 11/01/1975 - "Osteitis developed in 2 cases and was successfully treated with antibiotics within 6 weeks" 05/01/1968 - "Frequency and prevention of osteitis of the fracture line in the era of antibiotics]" 02/26/2000 - "In case of osteitis, after amputation with a healthy margin, antibiotics can generally be discontinued 2 weeks after surgery" Order ALL the reference details at left...
7.	Dihydrotachysterol (AT 10)IBA 05/01/1983 - "Dihydrotachysterol seems to be effective in the treatment of renal patients with osteitis fibrosa; its low cost makes therapy with this compound a reasonable alternative, although it should not be used in the treatment of patients with liver disease" 04/11/1950 - "Osteitis fibrosa generalisata with epithelial body tumor after a prolonged period of AT-10 dosage.]" 06/01/1979 - "Administration of dihydrotachysterol and 1 alpha-hydroxycholecalciferol to the patients on hemodialysis changed the mixed type of osteomalacia and osteitis fibrosa to the osteomalacic type with the marked reduction of osteoid seam thickness." 01/01/1984 - "The prevention and therapy of osteitis fibrosa and secondary hyperparathyroidism have been significantly improved as a result of adequate phosphate restriction and the use of active forms of vitamin D (primarily calcitriol in the U.S., dihydrotachysterol and 1 alpha-hydroxyvitamin D in Europe)" Order ALL the reference details at left...
8.	hydroxide ionIBA 01/01/1984 - "On the basis of these findings it is concluded that: the source of aluminium in our patients is aluminium hydroxide consumption and not the dialysis water; aluminium plays no role in the development of osteitis fibrosa; the findings are consistent with the theory that hyperaluminaemia plays a role in the development of osteomalacia, and serum aluminium measurement may be useful in the diagnosis of dialysis encephalopathy." 01/01/1978 - "These data, in conjunction with that from previous studies, indicate that therapy with 1alpha,25(OH)2D3 or 1alpha(OH)D3 does not heal the osteomalacia of renal osteodystrophy, but that it does suppress the secondary hyperparathyroidism, and ameliorate the osteitis fibrosa seen in patients with chronic renal disease" 10/01/1992 - "The effectiveness of CaCO3 without 1 alpha(OH)D3 derivatives in the control of hyperparathyroidism in dialysis patients has been proven by the appearance in four patients of our dialysis population of an histological idiopathic adynamic bone disease associated with relative hypoparathyroidism, and by the finding that more than 50% of our dialysis population treated by this sole treatment have plasma concentration of intact PTH below twice the upper limit of normal (that is, the threshold above which only significant histological osteitis fibrosa is observed)" 06/01/1983 - "Patients with mild to moderate osteitis fibrosa experience substantial improvement with either calcitriol or 1 alpha-OH D3 therapy" 11/01/1976 - "A long-term study on the comparative effects of vitamin D2 and 25-hydroxycholecalciferol [25-(OH)D3], in five patients with severe lesions of osteomalacia and/or osteitis fibrosa, demonstrated the efficiency of 25 to 200 mug/day of 25-(OH)D3 and the lack of therapeutic action of 345 to 685 mug/day of vitamin D2" Order ALL the reference details at left...
9.	Parathyroid Hormone (Parathormone)IBA 06/01/1996 - "Although osteoblast proliferation is a prominent feature of osteitis fibrosa, studies in vitro using osteoblast-like cells have shown that parathyroid hormone (PTH) impairs cell growth" 07/01/2002 - "Serum parathyroid hormone levels were significantly higher in patients with osteitis fibrosa than in asymptomatic patients (1,352.8 +/- 297.2 pg/mL versus 145.0 +/- 43.7 pg/mL; P<0.02) as well as in comparison with patients who had renal stone disease (P<0.02)" 11/01/1995 - "The intact parathyroid hormone PTH level was 187 pg/mL, a value rarely associated with significant osteitis fibrosa" 05/01/1990 - "All patients but one had elevated plasma concentrations of immunoreactive parathyroid hormone as well as osteitis fibrosa" 01/01/1989 - "Hypercalcemic patients with osteitis fibrosa had a significantly lower mean N-terminal parathyroid hormone (PTH) value than did nonhypercalcemic patients with osteitis fibrosa (149 +/- 81 vs. 278 +/- 135 pg/ml, respectively; p less than 0.005)" Order ALL the reference details at left...
10.	Alkaline PhosphataseIBA 01/01/1992 - "Since mean plasma alkaline phosphatase was normal, HPT was monitored on the plasma concentration of 1-84 PTH for which a previous histological study showed that frank osteitis fibrosa was present only when they were above 70 pg/ml, i.e" 09/01/1998 - "Alkaline phosphatase has been shown to be a fair marker for bone turnover in patients with osteitis fibrosa" 09/01/1998 - "Significantly higher serum levels of alkaline phosphatase were observed in osteitis fibrosa" 01/01/1982 - "Elevated serum alkaline phosphatase activity was associated with osteitis fibrosa" 03/01/1962 - "Lack of mineralization and the development of osteitis fibrosa are thus associated with a marked increase in alkaline phosphatase activity" Order ALL the reference details at left...

Therapies and Procedures

1.	Renal Dialysis (Hemodialysis) 12/01/1998 - "In summary, cases having undergone hemodialysis more than 10 years showed higher frequency of osteitis fibrosa when intact-PTH exceeded 500 pg/ml. Al-P values in such cases were high in association with the intact-PTH values" 11/01/1992 - "Hormonal markers of early-stage osteitis fibrosa in patients on hemodialysis]" 02/01/1990 - "I-PTH levels were well correlated with the severity of osteitis fibrosa evaluated by the degree of periosteal resorption in the digits of hemodialysis patients" 11/01/1986 - "In conclusion, these data suggest that a PTH RIA that uses an amino-terminal-specific antiserum may be a better predictor of osteitis fibrosa in patients undergoing maintenance hemodialysis." 10/08/1977 - "DHT, in doses of up to 1.0 mg/d, is effective in treating both the osteitis fibrosa and the osteomalacic components of bone disease in patients undergoing hemodialysis." Order ALL the reference details at left...
2.	Parathyroidectomy 06/01/1985 - "However, despite marked improvement in subperiosteal erosions and histological osteitis fibrosa, with significant reductions in iPTH and Ca X P product after parathyroidectomy, small peripheral arterial calcification developed or progressed in 56 per cent of the patients" 01/01/1996 - "CONCLUSION: Patients with high carboxyl-terminal PTH level and generalized fibrous osteitis were good suitable objects for parathyroidectomy" 11/01/1995 - "The latter showed osteitis fibrosa, and the patient underwent parathyroidectomy" 04/01/1988 - "Six years before this terminal illness he had undergone total parathyroidectomy for osteitis fibrosa associated with ruptured tendons" 09/01/1988 - "The aims of the study were to (1) determine the histopathology of parathyroid autografts in patients with renal failure treated by parathyroidectomy, (2) relate this to any evidence of hyperfunction, such as histological osteitis fibrosa and (3) determine whether there were any features in the donor parathyroid glands which correlated with autograft behaviour" Order ALL the reference details at left...
3.	Transplants (Transplant) 07/01/1995 - "An ideal bone graft material should prevent postextraction osteitis, and maintain bone in the extraction area and proximal to this site" 12/01/1989 - "Preliminary treatment of the recipient site and healing of open spongiosa transplant in post-traumatic osteitis]" 03/01/1982 - "Treatment of osteitis by excision and graft of spongy bone]" 04/01/1976 - "The authors present a new treatment technique of osteitis, which consists of an excision of necrotic bone followed by cancellous graft bone in two operations without a skin closure" 11/10/1975 - "Chronic necrotic osteitis of the jaw treated with a cartilagenous graft]" Order ALL the reference details at left...
4.	Debridement 11/01/2002 - "Factors associated with successful debridements included those done within 4 months of the index procedure, or in patients with less than 4 weeks of symptoms, antibiotic sensitive gram-positive organisms, well-fixed components with no radiologic evidence of osteitis, and in young healthy patients" 03/01/2004 - "Current therapy concepts for post-trauma osteitis include radical debridement, stabilization of bone and soft tissue care using early flap transfers" 02/26/2000 - "For deep ulcers, treatment duration depends on the presence or not of osteitis and the quality of surgical debridement" 11/01/1996 - "Sequential radical debridement and early soft-tissue reconstruction have considerably decreased the amputation rate, length of hospital stay, chronic osteitis, the rehabilitation period and secondary reconstructive procedures in lower leg injuries" 01/01/1999 - "A common problem of osteitis and septic arthritis is the recurrent bone infection after surgical debridement, a problem frequently encountered in patients with sequela leprosy" Order ALL the reference details at left...
5.	Prostheses and Implants (Prosthesis) 08/19/1978 - "An important aid is x-ray of the hip, in which the infection is manifested by osteitis and loosening of the prosthesis" 08/29/1987 - "Among the best indications are infected articular prosthesis, spondylodiscitis, osteitis and osteomyelitis." 03/01/2001 - "The most common histopathologic correlates of residual and recurrent hearing loss included resorptive osteitis of the incus (64%); obliteration of the round window by otosclerosis (23%); the prosthesis lying on a residual footplate fragment (23%); the prosthesis abutting the bony margin of the oval window (18%); adhesions in the middle ear (14%); and new bone formation in the oval window (14%)" 07/01/2008 - "Known clinical entities include osteitis/osteomyelitis, arthritis, prosthesis-associated infection and spondylitis/spondylodiscitis" 12/01/1994 - "In no case of osteitis was the infection cured merely by debridement and antibiotics, and the index prostheses were retained mainly in cases in which osteitis did not develop." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Osteitis

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 34 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>